-
Mashup Score: 35Are ADCs in lung cancer living up to expectations? - 2 month(s) ago
High rates of adverse events in the experimental setting seem to limit the potential of antibody–drug conjugates for patients with NSCLC
Source: dailyreporter.esmo.orgCategories: General Medicine News, Onc News and JournalsTweet
#ELCC24: High rates of adverse events in the experimental setting seem to limit the potential of #ADCs for patients with #NSCLC #ESMODailyReporter 👉 https://t.co/oNfcvJIYWC @DrJNaidoo https://t.co/TJeNO0gF68